Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (Nasdaq: ZURA) is a clinical-stage, multi-asset immunology company whose news flow centers on the development of novel antibodies for autoimmune and inflammatory diseases. Company announcements frequently highlight progress in its clinical pipeline, financial updates, and key corporate developments.
A major focus of Zura Bio’s news is tibulizumab (ZB-106), its lead investigational dual-pathway antibody targeting IL-17A and BAFF. Press releases describe the advancement of two Phase 2 trials: TibuSHIELD, a global randomized, double-blind, placebo-controlled study in adults with moderate to severe hidradenitis suppurativa, and TibuSURE, a global Phase 2 trial in adults with systemic sclerosis. Updates often cover trial initiation, enrollment status, study design details, and anticipated timelines for topline data readouts.
Investors and observers will also find quarterly and annual financial results reported by Zura Bio, including information on research and development spending, general and administrative expenses, net loss, and cash and cash equivalents. These releases typically include the company’s expectations about its cash runway and its ability to fund planned operations and clinical programs.
Additional news items include corporate and leadership changes, such as executive appointments, board transitions, and the establishment of advisory structures, as well as participation in healthcare and investor conferences where Zura Bio presents corporate overviews. The company also issues updates related to equity inducement grants and other compensation matters.
This news page aggregates these disclosures so readers can follow Zura Bio’s clinical milestones, financial condition, and organizational updates in one place. For those tracking ZURA, the feed offers an organized view of how the company’s immunology programs and corporate strategy are evolving over time.
Zura Bio (NASDAQ: ZURA) has launched TibuSURE, a global Phase 2 study evaluating tibulizumab for treating systemic sclerosis (SSc) in adults. The study marks the first clinical trial designed to investigate both anti-BAFF and IL-17 pathways in systemic sclerosis. Tibulizumab's dual-pathway approach aims to provide deeper efficacy compared to single-pathway inhibition, which has shown modest effects in rheumatic diseases like SSc.
The company believes this novel strategy of concurrently targeting two pivotal pathways involved in inflammation and fibrosis could address the multi-organ pathology of SSc, a heterogeneous and complex autoimmune disease with effective therapies currently available.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focusing on dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's senior leadership team will engage in a fireside chat on Tuesday, December 3, 2024, at 9:00 a.m. ET in New York, NY, and will conduct investor meetings. A live webcast and replay of the presentation will be accessible on the company's website's Investors section under 'News & Events,' remaining available for at least 30 days after the event.
Zura Bio (Nasdaq: ZURA) has submitted a protocol to the FDA for a Phase 2 study of tibulizumab, a dual-pathway antibody targeting IL-17A and BAFF, for treating systemic sclerosis in adults. The planned double-blind, randomized study will evaluate safety, tolerability, and efficacy in approximately 80 participants with early diffuse cutaneous systemic sclerosis. The trial aims to demonstrate improvements in skin and lung symptoms and includes an open-label extension. Expected to begin in Q4 2024, the company has already submitted an Orphan Drug Designation request to the FDA.
Zura Bio (NASDAQ: ZURA) reported Q3 2024 financial results with a net loss of $22.9 million ($0.26 per share), compared to $8.3 million ($0.18 per share) in Q3 2023. The company maintains a strong cash position of $188.2 million, expected to fund operations through 2027. Research and development expenses increased to $6.0 million, while general and administrative expenses rose to $13.3 million.
The company plans to initiate Phase 2 trials for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025). An Orphan Drug Designation application was submitted to the FDA for systemic sclerosis treatment.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company focused on developing dual-pathway antibodies for autoimmune and inflammatory diseases, has announced its participation in two major investor conferences this November. The company will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on November 12, 2024, at 1:00 p.m. ET in Boston, and will host investor meetings at the Jefferies London Healthcare Conference on November 21, 2024, in London. Webcasts and replays will be available on Zura Bio's website's News & Events page for at least 30 days after the events.
Zura Bio (Nasdaq: ZURA), a clinical-stage immunology company, has announced its participation in three upcoming investor conferences in September 2024. The company will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 11:30 a.m. ET, the Stifel Immunology and Inflammation Virtual Summit on September 17 at 12:00 p.m. ET, and the Cantor Global Healthcare Conference on September 17 at 2:30 p.m. ET.
Zura Bio's senior leadership team will host investor meetings at these events, with the Stifel summit being virtual. Live webcasts and replays of the presentations will be available on the company's website for at least 30 days following each event.
Zura Bio (Nasdaq: ZURA) reported Q2 2024 financial results and business highlights. Key points include:
- Presented tibulizumab data at EULAR 2024, showing potential for dual inhibition of IL-17A and BAFF in autoimmune diseases
- Plans to initiate Phase 2 studies for tibulizumab in systemic sclerosis (Q4 2024) and hidradenitis suppurativa (Q2 2025)
- Appointed Robert Lisicki as CEO and formed Scientific Advisory Board
- Cash position of $188.4 million as of June 30, 2024, expected to support operations through 2027
- Q2 2024 net loss of $12.7 million ($0.17 per share)
- R&D expenses decreased to $5.5 million, while G&A expenses increased to $6.2 million
Zura Bio (Nasdaq: ZURA) has completed its exchange offer and consent solicitation for outstanding public and private placement warrants. The company issued 3,235,184 ordinary shares in exchange for tendered IPO warrants. Zura Bio will exercise its right to exchange all remaining untendered IPO warrants at a ratio of 0.27 Class A ordinary shares per warrant on August 27, 2024. As a result, no IPO warrants will remain outstanding, leading to their suspension from trading on Nasdaq as of August 26, 2024, and subsequent delisting. The company's Class A ordinary shares will continue to trade on Nasdaq under the symbol 'ZURA'.
Zura Bio (Nasdaq: ZURA) has announced the expiration and results of its exchange offer and consent solicitation for outstanding public and private placement warrants. 97.2% of public warrants and 69.0% of private placement warrants were validly tendered. The company expects to accept all validly tendered IPO warrants for exchange and settlement by August 12, 2024. The consent solicitation received approval for the Warrant Amendment, allowing Zura Bio to require conversion of remaining warrants at a 10% lower ratio than the exchange offer. Zura Bio plans to execute the Warrant Amendment and exercise its right to exchange all remaining untendered IPO warrants, after which no IPO warrants will remain outstanding.
Zura Bio, a clinical-stage immunology company (NASDAQ: ZURA), has announced an exchange offer and consent solicitation for its public and private placement warrants issued during its initial public offering. The company aims to simplify its capital structure and reduce potential dilution by offering 0.30 Class A ordinary shares for each outstanding IPO warrant. This exchange offer could result in issuing up to 3,842,999 new shares, an approximate 6% increase in outstanding shares. Concurrently, Zura Bio seeks consents to amend the warrant agreement to enforce the exchange of all remaining warrants at 0.27 shares per warrant if the offer succeeds. The offer period ends on August 8, 2024. Parties holding 40.7% of public warrants and 65.3% of private placement warrants have already agreed to tender their warrants.